Trump Administration Cuts $46 Million in Direct HIV Prevention Funding to Community Groups

The Trump administration has ended direct federal funding for HIV prevention work at 96 community-based organizations across the country, cutting $46 million that had been earmarked to run through May 2027. The decision came from the Office of Management and Budget at the White House’s request and took effect immediately.

The money isn’t being eliminated outright — OMB is redirecting it to state governments instead. But states aren’t required to pass any of it on to the community organizations that were actually doing the work. That distinction is the whole fight: advocates say it swaps a direct, accountable funding line for a discretionary one that depends on 50 different state health departments choosing to prioritize HIV prevention in their own budgets.

What the money paid for

The eliminated grants funded HIV testing, referrals into medical care, and distribution of PrEP — pre-exposure prophylaxis, the daily or injectable medication that’s roughly 99 percent effective at preventing HIV infection when taken as prescribed. For many of the affected organizations, this funding wasn’t a supplement to their HIV work. It was the infrastructure underneath it: the outreach workers, the testing events, the relationships with people who don’t otherwise have a reason to walk into a clinic.

Organizations losing direct funding include Whitman-Walker Health and La Clínica del Pueblo, both in Washington, D.C. — two of the longer-standing community health providers serving LGBTQ+ people and immigrant communities in the capital. Reporting from Ohio has flagged similar losses at Equitas Health, one of the largest LGBTQ+-focused health systems in the Midwest.

Advocates call it dismantling three decades of infrastructure

Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, helped organize a July 22 letter signed by 71 community-based organizations opposing the change before it was finalized. Their warning was blunt: “Ending this program without a clear plan for what comes next would dismantle prevention infrastructure that has taken more than three decades of federal investment to build.”

That’s not rhetorical flourish. The direct-funding model being unwound traces back to the earliest years of the domestic HIV/AIDS response, when it became clear that health departments alone couldn’t reach the people most at risk — and that community organizations embedded in those communities could. Routing the money through states instead reintroduces exactly the gap that model was built to close, at a moment when new HIV diagnoses are increasingly concentrated in the South and among Black and Latino gay and bisexual men, populations that already face the steepest barriers to a doctor’s office.

There’s also a quieter, practical consequence advocates have flagged: PrEP drug-assistance and discount programs are often tied to enrollment through the very community organizations now losing their direct grants, which could complicate whether patients already on PrEP stay covered while the funding shakes out at the state level.

Part of a broader pattern

This cut doesn’t arrive in isolation. It lands amid a string of Trump administration actions this year narrowing federal support tied to LGBTQ+ health and rights more broadly, and as advocates separately warn that funding uncertainty is complicating planning for the upcoming International AIDS Conference. Taken together, the moves represent a meaningful federal retreat from a decades-old, bipartisan public health consensus that ending the HIV epidemic requires sustained, direct investment in the organizations closest to the people who need it.

No timeline has been announced for whether or how states will replace the direct funding, leaving the 96 affected organizations to plan for the next fiscal year without knowing what, if anything, will be left of a grant program that’s been running since before many of their current staff were born.

Sources: Washington Blade; AIDS United; Roll Call; STAT.